Skip to main content
. 2016 Jan 14;22(2):823–832. doi: 10.3748/wjg.v22.i2.823

Figure 2.

Figure 2

Synergistic inhibition of proliferation of liver cancer stem cells targeting β-catenin and Ras/Raf/MAPK pathways. FH535 and Sorafenib combination on inhibition of [3H]-Thymidine incorporation in liver cancer stem cells (CD133+, CD44+ and CD24+) Calculated combination index (CI) of less than 1. From Galuppo et al[12] with permission of Anticancer Research.